Global End Stage Renal Disease Market
Dublin, Sept. 19, 2022 (GLOBE NEWSWIRE) -- The "Global End Stage Renal Disease Market Size, Share & Trends Analysis Report by Treatment (Transplant, Dialysis), by Region (APAC, North America, MEA, Europe, Latin America), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.
Increasing number of patients suffering from kidney failure, rapid increase in the volume of hospitals & urgent care centers, and growing hospital admission rates are among the few factors propelling the market growth. Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients. According to the CDC, it is estimated that more than 37 million people in the U.S. suffer from CKD, whereas globally more than 500 million people (12-18% of the world population) are affected.
As a result, increasing the demand for dialysis or kidney transplant. The COVID-19 pandemic has impacted the healthcare industry and people suffering from ESRD are at a higher risk of contracting this virus, as they have to visit the hospitals often for dialysis. Center-based hemodialysis is the main renal replacement medium in most countries, with almost 90% of the ESRD population opting for it. Hemodialysis patients have to stay in hospitals for 4 hours minimum, 3 times a week, and come in frequent contact with the medical staff and other patients.
All these factors increase their risk of infection. Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD. For instance, the innovation of Wearable Artificial Kidney (WAK) technologies, a portable dialysis device designed to enable patients to live a healthier life as it controls blood pressure, improves clearance of wastes from the blood, and allows ESRD or CKD patients to a less strict diet, and results in lower fluid weight gain in addition to lowered stress on the heart.
Thus, technical advancements in WAK have the potential to reduce mortality in dialysis patients, which thereby improves an ESRD patient's quality of life. The WAK prototypes designed and patented by innovative firms have been approved for human clinical trials by the U.S. FDA in 2016.
End Stage Renal Disease Market Report Highlights
The dialysis segment dominated the global ESRD market in 2021 owing to its ease of use and emergency convenience.
this segment is further sub-segmented into peritoneal, hemodialysis, and wearable artificial kidney.
The Asia Pacific region dominated the market with the highest revenue share in 2021 and will expand further at the fastest CAGR from 2022 to 2030.
This growth can be attributed to the large population of patients with CKD/ESRD, and the greater incidence of hypertension and diabetes in the continent.
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. End Stage Renal Disease Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.4.2 Market Influencer Analysis
3.5 List Of Key End Users
3.6 Regulatory Framework
3.7 Market Dynamics
3.7.1 Market Driver Analysis
126.96.36.199 Growing Prevalence Of Diabetes And Hypertension
188.8.131.52 Introduction Of Technologically Advanced Products
184.108.40.206 Increasing Number Of Patients Suffering From Chronic Kidney Disease
3.7.2 Market Restraints Analysis
220.127.116.11 Risk Of Complications
18.104.22.168 Stringent Regulatory Policies For Dialysis Products
3.8 End Stage Renal Disease: Market Analysis Tools
3.8.1 Industry Analysis-Porter's
3.8.2 Swot Analysis, By Pest
Chapter 4. End Stage Renal Disease Market: Segment Analysis, By Treatment, 2018-2030 (USD Million)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2021 & 2030
4.3 Segment Dashboard
4.4 Global End Stage Renal Disease Market, by Treatment, 2018 to 2030
4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
22.214.171.124 Dialysis market, 2018-2030 (USD Million)
126.96.36.199 Transplant market, 2018-2030 (USD Million)
Chapter 5. End Stage Renal Disease Market: Regional Market Analysis, By Treatment, 2018-2030 (USD Million)
Chapter 6. End Stage Renal Disease Market-Competitive Analysis
6.1 Recent Developments & Impact Analysis, by Key Market Participants
6.1.1 Nipro Corporation
6.2 Company Categorization
6.2.2 Market Leaders
6.3 Vendor Landscape
6.3.1 Key Customers
6.3.2 Key Company Market Share Analysis, 2021
6.3.3 Major Deals And Strategic Alliances
188.8.131.52 New Product Launch
184.108.40.206 Marketing & Promotions
6.3.4 Market Entry Strategies
6.4 Public Companies
6.4.1 Company Market Position Analysis
6.4.2 Competitive Dashboard Analysis
220.127.116.11 Market Differentiators
6.5 Private Companies
6.5.1 List of Key Emerging Companies
6.5.2 Regional Network Map
6.5.3 Company Market Position Analysis
6.6 Company Profiles
18.104.22.168 Company Overview
22.214.171.124 Financial Performance
126.96.36.199 Product Benchmarking
188.8.131.52 Strategic Initiatives
6.6.2 Fresenius Medical Care AG & Co. KGaA
184.108.40.206 Company Overview
220.127.116.11 Financial Performance
18.104.22.168 Product/Service Benchmarking
22.214.171.124 Strategic Initiatives
6.6.3 B. Braun Melsungen AG
126.96.36.199 Company Overview
188.8.131.52 Financial Performance
184.108.40.206 Product/Service Benchmarking
6.6.4 Baxter International, Inc.
220.127.116.11 Company Overview
18.104.22.168 Financial Performance
22.214.171.124 Product Benchmarking
126.96.36.199 Strategic Initiatives
6.6.5 Asahi Kasei Medical Co., Ltd.
188.8.131.52 Company Overview
184.108.40.206 Financial Performance
220.127.116.11 Product Benchmarking
18.104.22.168 Strategic Initiatives
6.6.6 Cantel Medical
22.214.171.124 Company Overview
126.96.36.199 Financial Performance
188.8.131.52 Product Benchmarking
184.108.40.206 Strategic Initiatives
220.127.116.11 Company Overview
18.104.22.168 Financial Performance
22.214.171.124 Product Benchmarking
126.96.36.199 Strategic Initiatives
6.6.8 Nikkiso Co., Ltd.
188.8.131.52 Company Overview
184.108.40.206 Financial Performance
220.127.116.11 Product Benchmarking
18.104.22.168 Strategic Initiatives
6.6.9 JMS Co. Ltd.
22.214.171.124 Company Overview
126.96.36.199 Financial Performance
188.8.131.52 Product Benchmarking
184.108.40.206 Strategic Initiatives
For more information about this report visit https://www.researchandmarkets.com/r/4j55lx
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900